Prometheus Biosciences, Inc. (RXDX) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は San Diego, CA, アメリカ. 現CEOは Mark C. McKenna.
RXDX を有する IPO日 2021-03-12, 97 名の正社員, に上場 NASDAQ Global Select, 時価総額 $9.56B.
Prometheus Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and companion diagnostics for inflammatory bowel diseases (IBD). The company's lead candidate, PRA023, is a humanized monoclonal antibody currently in Phase IIa clinical trials for ulcerative colitis, Crohn's disease, and systemic sclerosis-associated interstitial lung disease. Prometheus maintains a robust pipeline including multiple therapeutic programs targeting different disease mechanisms in IBD and immune-mediated conditions, supported by strategic partnerships with leading pharmaceutical companies including Takeda, Dr. Falk Pharma, and Millennium Pharmaceuticals. Headquartered in San Diego, California, the company was incorporated in 2016 and formerly operated under the name Precision IBD, Inc. before rebranding to Prometheus Biosciences in October 2019.
